Cabaletta Bio is a late-stage clinical biotechnology company focused on developing targeted cell therapies specifically for patients with autoimmune diseases.
The company’s statements of operations do not report any top-line revenue.
The net loss per share (basic and diluted) was $(0.40) for the fourth quarter of 2025 and $(2.10) for the full year 2025.
Full-year research and development expenses reached $142.7 million, contributing to a total net loss of $167.8 million for 2025. Cabaletta Bio ended the year with $133.6 million in cash, cash equivalents, and short-term investments. Combined with an additional $30.0 million raised in the first quarter of 2026, the company expects its capital to fund operations into the fourth quarter of 2026.